TickerGuard
Buy Day today: Neutral (50) Mixed market breadth · no major macro event
TRLV

Trulieve Cannabis Corp.

Healthcare · Drug Manufacturers - Specialty & Generic

9.50$ -1.7% vs. previous close Closing price · As of: Aug 17, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Trulieve Cannabis Corp. (TRLV). It shows which part of the business is growing — and which one is holding it back.

Revenue by product line

Revenue by product line — TRLV
Segment 2020 2021 2022 2023 2024 2025
Retail $520.2M 99.7% $869.7M 93.3% · +67.2% $1.16B 95.1% · +33.2% $1.08B 96.0% · -6.5% $1.13B 95.1% · +4.2% $1.11B 94.0% · -1.6%
Wholesale and other $59.8M 4.9% $45.6M 4.0% · -23.6% $57.6M 4.9% · +26.2% $70.7M 6.0% · +22.8%
Wholesale, Licensing and Other $1.3M 0.3%
Wholesale $61.1M 6.6%
Licensing and other $1.1M 0.1%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: August 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?